Auvi Labs | Heinz Ventures Portfolio
Auvi Labs is an early-stage medical technology company developing Beacon, a wearable ultrasound patch that noninvasively monitors dialysis vascular access and alerts clinicians to early signs of failure. For patients on hemodialysis, the arteriovenous fistula that makes treatment possible is prone to silent failure — and today's monitoring often depends on subjective, intermittent observation. Beacon is designed to make that surveillance continuous and objective. Developed by founders out of the University of Illinois and Carle Illinois College of Medicine, Auvi Labs is a Heinz Ventures portfolio company, and Eric Heinz serves as Board Chair.
-
Heinz Ventures relationship: Investor
-
Eric Heinz role: Board Chair
-
Sector: Vascular surgery / Interventional Nephrology
-
Stage at investment: Pre-seed
-
Location: Chicago, Illinois
Why it fits the Heinz Ventures thesis
End-stage kidney disease is a large and growing population, and vascular access failure is one of its most costly, dangerous, and recurrent complications. The gap between that clinical need and today's subjective monitoring is exactly where a differentiated, regulated technology can create durable value.
Auvi Labs maps onto the thesis on each axis Heinz Ventures looks for: a clear unmet clinical need; differentiated intellectual property in its wearable-ultrasound sensing and signal-processing approach; a noninvasive, point-of-care form factor; and strategic relevance to dialysis, vascular, and kidney-care players as the technology reaches clinical milestones. Its origins in the University of Illinois medical-technology pipeline reflect the kind of rigorous, clinically grounded engineering the firm favors.